-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 GFBXTSj/tv0f448qSAplVLkzmIcyEJzxO7Yse4sCTO+gk4SdJFMBEPu2RnfqiPU8
 qExMwjowYrdhDhYmGI5XFQ==

<SEC-DOCUMENT>0001144204-07-052444.txt : 20071002
<SEC-HEADER>0001144204-07-052444.hdr.sgml : 20071002
<ACCEPTANCE-DATETIME>20071002163827
ACCESSION NUMBER:		0001144204-07-052444
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20071002
FILED AS OF DATE:		20071002
DATE AS OF CHANGE:		20071002

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		071150292

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v089316_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      October 2, 2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>711
      Executive Blvd., Suite Q</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Valley
      Cottage, New York 10989</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="25%">&#160;</td>
            <td width="25%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font size="2">Form
                20-F <font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font></div>
            </td>
            <td width="25%"><font size="2">Form 40-F <font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></td>
            <td width="25%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="25%">&#160;</td>
            <td width="25%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font size="2">Yes
<font face="Wingdings">o</font></font></div>
            </td>
            <td width="25%"><font size="2">No <font face="Wingdings">x</font></font></td>
            <td width="25%">&#160;</td>
          </tr>

      </table><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt"></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div>&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><IMG SRC="v089316_logo.jpg"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Incorporation
      by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated October 2,
      2007
      is hereby incorporated by reference into the registration statement on Form
      F-3
      (File No. 333-141529) filed by XTL Biopharmaceuticals Ltd. with the Securities
      and Exchange Commission on March 23, 2007.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>AGM
      / EGM STATEMENTS</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Valley
      Cottage, New York, October 2, 2007</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      - XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announces today
      that
      at its Annual General Meeting and Extraordinary General Meeting held earlier
      today, all the resolutions proposed to the shareholders were approved.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      cancellation of the listing of the Company's Ordinary Shares on the Official
      List of the United Kingdom Listing Authority will take place at 8:00 am (London
      Time) on October 31, 2007.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the development of therapeutics
      for the treatment of neuropathic pain and hepatitis C. XTL is developing
      Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
      of diabetic neuropathic pain. XTL is also developing several novel pre-clinical
      hepatitis C small molecule inhibitors. XTL also has an active in-licensing
      and
      acquisition program designed to identify and acquire additional drug candidates.
      XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges
      (NASDAQ: XTLB; LSE: XTL; TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(845)-267-0707 ext. 225</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>XTL
              BIOPHARMACEUTICALS LTD.</strong></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:&#160;October
              2, 2007</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;Ron
              Bentsur </font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="60%"><font size="2">Ron
              Bentsur </font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                Executive Officer
</font></div>
            </td>
          </tr>

      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>v089316_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v089316_logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/0"D`P$1``(1`0,1`?_$`,T````%!0$!````````
M```````("0H+`0(#!@<%!`$``0,%`0``````````````"``"!P$$!08)`Q``
M``4#`@,$!@0)"`L``````0(#!`41!@<`""$2"3%!$Q1182(5%@IQ,A@Y@9&A
MP6(SLW9WT2,DM+76EUCPL?%"4F,U1387&1$``0($!`(%!P8*"`8#`````0(#
M`!$$!2$2!@<Q05%A<1,(@9&Q(C(4%:'!<B,6-M%"4I*RTG-4=!?A\6(S@Y,D
M&/""PD-3-"4F"?_:``P#`0`"$0,1`#\`?X%/S4]H1Y@J%![::\0D#VG)B*!:
MC^)*-+R1?D#BZP+XR5="JJ-NV#:-PWC.*I%%18(JVXEW,/RH$[3N#-F9@('>
M:@:]J2FJ+A5MV^D("G5!()XS)EYH\:NK;I*1=142[M`)('4(9(3GS8N61S46
M9MO;U;1]O:,D9((!V^`<@RD"1X*2<PE<7B%9,EG,?1<&YFAC$,/()A'CHG:/
MP[BILB<]=_\`+A&8S'J2E/#^O'C$'O;P%-Q4RA$J1)E(@S"I\.'DX<>?.'F^
MW7.-I[D,'XYSE97F4[9R5;$==$:S=T\ZP3D42+&CG8@!0%RS,;D/P"HAV:&J
M\6RIM5VJ+8^Y,L**20,,/FB9K37MWBWLUJ?52\F<OFCM0FY:`(#6O"H@%.SB
M'JU8I<4@95%(5YHR)!7)67A%P5[N;\6JI"/^Z$YNJ$3FQ(/GBOM?I?BT[ZCH
M$4E]+SP/:_2_%I?4=`A2^EYX'M?I?BTOJ.@0I?2\\6^(`&Y1K6E>(<*"-/R:
M;G:"LJ03V0BE/%2I#H,92B`CP`.SM#7MQ$-'=YO5XQDU2'Q\5033`!JH%>P`
M[`[N'=KP+BF7"MXDSPP&$,S.M"7K..<^F/H1$!*(@(CQ_P!X:B'`.'=33V^$
M\V8$\82)2PG/G/C.+CE`P4'TUTG4YDRZX<4@\8^8Q^4]"B!0`*B'I^GUCJCB
MW%HDV,>F**0ZI0=4L!L0`,54"\IA`*B%!#VN'\O=J@J&F7,BU36J/0H2,%IS
M'ICZ$Z`6@5X#3C_L#5PKC.&R`P``'5&3384#2A0-*%"+?6T/O6LO:NKF[9-E
M>X[`NK#CU>?OZW8!LP<FNRQG":1)5T!7C!^8'-N(H&7(4H!XG.(!V:WS;=K3
M=3J%%!J=`50OX((D,JN6:?*-.UP;RQ:U5EG<4EU/$=7DAG=MPZY6[F8RE&65
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M5PWNHHYCWIB-95Z@"C4H"'*0XUJ(ZR&G]J[9>:5>H=8MRN%Q45@#`-@XX@QC
M-0ZUKK+5MV>R.`4=,`$RG,GK,Y&%H-K.9NIC$=*+=#OXW'[EKS5N&XL8R4SM
MWMN290K5Q:L7&D6,CD%TM[H01,>X05`&R(@(I^7$3A[0!J(M26?1CVX5%I'3
MS:/=RL!YPF:<.($N'7/IB0;77:A:T=57:XK6JXH$VP,!VGCAR$CRX#A#:Y#K
MT]4`$4Q-O%NT]4TQ$WAVG41$@"(_]%[Q'1`HV?VY`!4EI24@3Q&)EC+&(G.N
MM<S(2XXF1(D4GICT$>NSU3G!!60W<WFLC7EYTFMKJ%`WH$Q(,Q:_AUZ?RBVY
M?3.EI<PG*<P8M7-R-8,J[IU]0>E.13+#RQC4Z\'5%0/X:^\"[D3T`>15"UDS
M4$*E$2G@Z\=>:MH=NVE=V\TVAP])'X8]&MQM9K3G2MU:.I/X)Q:3KQ=4510$
MD]X5V**CP*FFE:AS&'T`4L)S"/T:>QL[MRM:62EE3B^&4_TF'.;AZU">\"W4
MM])3_5!\^F9U>NHGG/?7M[Q9E#<K=UU6'=UT&87';[MK`IMI-KRI#X*QFT.@
ML4H#7ZIP'B.M5W#VMT?8-*UMRMK.6K8;FD\ISC.:4UEJ"[7QBFKWBIMQ821U
M$$],N42')/KCQX!4`#NH`^C0:GB%<\8)0`!&`'&,VG12&V5\;P=R$7U5(C!3
M#*<XVQ4\S?;MJ*V@1./\B,$_7`CEB"AF8N>0Y1_XZ^O1QVC:+1-5X='M=/TY
M5J!-K>?"\)9T":?)TQS:ON]6X%/XLV=OZ2L6G32[LU3J;_L+("NJ?1A#D5,]
M!.6GL@8P`/=P&E-`OD#)F"`@B<NN.DBE26$2/`&?;%5#CP"H!7@'>-=5&9P^
MJ1DYQ216O)/""P;R)O(MM[;<M3F)QF`R-'6FX7M(;>9GD)?WL5TT*EY)DF@Y
M477%(3T`$S<.[6X;?4]IK=84%'?%)1IUQ\!Y1(!"<<9G#SQ'>[3FH:;;JZ5N
MEPI6H&6"JG2)XJF)3EB?)!/NE=D/=#D#'^07>YM:^%IYE<1$[?\`C>"6@7A(
MPYE:@V06CHXRR0@0*&H;AV]NI)W^LNWECOE$SH);3]&XP%+*%)5)7/%),HB7
MPOW?<RZ6"M7N;WPJVGLK?>`@Y<>D=/#JA5],_LCPI3T]M:?GU!"BXI.9(D>B
M">FC$H([OIZXJ90_"E*"'>`U'UZ1"^[GP7#P`49DD$Q=S#2O,4/IU5M*P).2
M)ZHJ)$8#&,O=_I358;'ERL0PFH]]$RC)K(QDFT<,)&/>(D7:O63I,4G#9PBJ
M4Z:J2J9A`Q3`("`TTU!<:=#S9DY,8]$NB*.H;?94RZ)H4)1&3]<+IHR6P;<Y
M*2]M,SN=OV<I29N3';DB"HH6^]="H\FK->N!(5$7C=4RRR=/9\`Y0"G9H\-I
M=>'4^GFZ-R2KK2^HM)QFW+`CG`L:_P!,U&G[B:AC_P!1U69)'$$&?G'5!A\=
M]<^_K(Z2ER;-Q?2RVX1"4'&-FWT9VL99#"\M'*/7<NLL8XG3=P@@$*BD4:"V
M/S4X!36;CM'3O;@B^-%L6M0[THECW@/"7"1XGKB]9W">:TJ+8@K][0<@,Q[$
MN$SC/HY03;HZ=/"3Z@&[2U;7G6+PV$,;/V=XYBFDB./+O8J-.1RTM(DCRF*C
M+3:HD$HB(\R:9ZZW#=;6C6B-**6C*[=*A.5"`<4`B4P.H8X1B]`::^T]V]YJ
MI^[H,U3XF71V\,>7*)/0V-[(/9C?':]IVX^L-M$-8$EG2$+&O+;-#M&Y&R,<
MI#.&JD:HT\(E!3,F)/5QT!OO-0ESWEE135@S"YD*F>./&"I##*6/=<H+)$I=
M4<K':-M5)RTVR[?@H`%*!<.X\Y0``X!_XX`T#T:O1J#4"02JLJ,>AQ?ZT8I=
MAL^8*-,T0#^2/P1'S_,<V596/^HC(VW85HVO8\$ECNW'`0EGV[#VS$>.Y:,5
M3K^[H5FR:"L83#4_)S#7MT96P=2]4Z:-77NN._6J3)1*C@>DDF!YW6IZ6EOW
M=4S24#NTGU0!B9GEPA>CY9;!>%,E;";DFLBX=Q9?LVCE^[&B4Q>>/[3N:5(T
M([6\)L62FHE\]\!(H`!"<_*4.``&H@WUNETHM8"GHWW6V^ZF`E:DC$\Y$8QO
M^V-JMU;IU3E2TA:BN6(!Y0>OK.;;-O=H]-G<Q/VE@G#5J3\=9IEXZ=MS&%DP
MTPR6*8P<[24CH-L^:*<?KIG*8/3K4ML[Q='M=6YE^I?4@O`*!6HB1ZB2(V+6
MUHMM-I1\LLMI6A,YA(GAT&&-71N$P]2?:B)AYA^+25&A0[$$0[NWZ1XZ+7=9
MH-:%N@!F"B8^2($T(0=3TTN`?'H7$K$'ZT?PZY[\QY?28+X>QY8S:=#(:`YI
MN")M;K)(W///THF`MO/EN3,S).#)D09Q[%45':ZISC0"$)V]^NF>E6JFN\)#
MM/2-..5#EM=IT)`F5+<P!`Y@<^<<?=;5E!9_&C\5KG$M4=-=VWW%*,@E*/65
M,])'#E!Y\H]<-PK<,I$[=<`3F1(F*D7C!U<5P-YXT>_!LX4;@[CBVDA('2;K
M*$'E\;E-3CJ#;)X4%NVQBMU7>Z*WUSS:5!I13-(/`*S2.;IPE!':B\:;K5T?
MH]%:=K;K;FG"GO@%$$CFG)^+T8SCH&WKK98RR!<\+9&;+`E<33\M)MXD9I%4
MZ]JLI!RH5LW0?)R8ISK,5%S%*!CH@4*\:<1UCM;>$K5-@T^[JBPU]-<K8P)J
M;;Q<(Z4Y9@X8QE-`^-+3.I-0-:6U1;GK3<'B`%K5)"23*2LV/5"L6<LPQN&,
M-WUF=:/<7!$V1;JER&91:Z/C2S5)5NDF1DX%0&XD6*X`P&YJ"`:&32%@J-6Z
MDHM*MS8K*NL+*2H2"3CBH<9805FM]9T^B]'7'6"&_>F*2C[\!)!"TX<#Y8X1
MLAWJ0F]2RKDOB`LV9LUM;DZX@58^:<MG2[E4@@`.4S-E5DR)"7C2M=;[N[M-
M4;2Z@I;/7U(J:AZF#@4D$``\C/&<:1LCO)1[RZ;J+U34JJ8-/Y"DD*/3,2)P
MEYHT?>%U*,'[0GJ=M3A)*^\@.$5%O@^U7#(7444$^9NM-+N7"*#5)53V>3F%
M7]$*@.LAM9L3K3=3O;A;O]+9*=/K.NS"29F>0RQ,L>B,!O#XCM$;0)%!6GW[
M43JB$T[,LR<!(KZ!/#IA,T_6YS\*WOLNTHGP&8?'3ECI7X+LK/FYO$.L1@:+
M,<4N(&!04Z]]-38WX4=,Y@T[JFE3<SADFF0)ZIS^2!U'C:U9D]Z^R-6;?F]H
M)<`R],_9ZX4TV<=2C"&[Y=2V(5.4LK(C=$JBMF70LP([?`0H>.O#JMESINT2
M'X`01\4`[0X#J'-T]A-7[3N)K:]::RR.":7V@2CJ!F)`_)!(;/>(W1N[Y7;J
M+-07QN0++I&92N81S,N!'5"C_,6G:'9^;4)YAQY0068>S,9HOKJL.A%GKW8?
MP-E3IUY<?YQN9I9)<?-T;JQ]=BG(9ZSODIBH1<(R1.8`6-=:I4V"@`',4BO-
MV%XR)M5<KM0:S819B55#IRK3_8)Q)Z)=,:1N!2TM3IQUQ^6=H%2>V7*(POQ5
MQ;)G4+R+BW)S%Y0$Y53)`;E,;M'E-P`!T?[YI<B6I'WU2?(%RZ>V!$]IU009
MM9S(](!^<8Q)1_+K6SMIANGI:,M@-^24N6X9J45S1(R";=&XDL@-5_#>Q<BB
MFJJJG%QISJ$C^;@9$1$.\``7==Z]KU<ZQ>"H*;/J#'*4\B#P/7*"MV\IJ!BP
M-N4V7OW?:E(GEYO+"^^HVB18PJ]WTZ:OV8\W/9\T1P?S-'WETM_#6T_[/8Z-
M;8'[FG^(7^E`S;N_>3_#1^BJ'#7RL'W?%T?QFN[^M+ZAS?[[\)_AQZ8DO:;[
MLG]K\PA0'K??=A[H_P!R5/V@ZTO;#[_V_P#;I^>-CU[]U:SZ!B/^Z-WWDVU'
M]["_L4=&?NX/_HMR_9#YH''07WFI_P"('_7$K$'ZT?P_ZM<\>8\OI,&`/8\L
M9M.AD,E-^5INK^ZD^0["8*&(O>64(RWFQB?7!:36(B`E'M`0_-KJ[M!>&['L
M#17BL(31T5O6XD<E*`)$_-'$??.S5&H/$Q=K"R,U1679MN8XA*BD2'D./9#N
M;!NWG%F#L>6[9EBV="Q",="Q[=Z\*S1-(2;H&Y#NG$D]$A5WBRCDYAJ<1IP#
MNUS%U-K&^:JOCUWN54XZMQY2TC,0$()P`'"0CKYHW0>G=&:>9L=EI&FN[80E
M2BD$K7E$R2<2281IZT6T6Q$,7L=R=BP+"U[FM>328WLK#MDFC2<A)!8$VKMV
MU1*1,9-O+K)T7&I^0*:*OPB[G71C5#VA[FKWNVUJ?4S*)R'@1CR(Y0&7C4V>
MLSNEV=P[.V*:\T2P%I2`D+!,RK#F.,;9CG,\GFCHW93?3[DSJ;M"P[BLMZJ<
MH`8S6!E(]G%&.;F$3J':)!4W?2NL3?\`2;>C/%7;[4A`13/W!#R`.6<*)`Z)
M1F+#KG[=>#6Z7%;BA74EN6PX3Q]0H$_+&A]&F^8_&>T#<-D26`1C;*G;AN-Z
M0H\IC-HIHJZ5`!#B'!/6P>+JSNZDW0LMII#]>^TRV.TJE+Y8P'@PO*--[3:A
MOE09L404X?\`E:4KYH)OTZ\#I[Y]VF3,S9E(>X+5MR6<W;,LW2@BVGIN4DEV
M\%'+$$#@9BQ;M43'2XE.%0$*#J0M^=6L[-[86O26F5K8JWT!ES+^4$@J5RXY
MI3B(?#?HM>^N\-TUUJ8*?H*=9>0%>R0I9"4XGB)<(=??!EJ(PA+<+;D*$"5L
M#)*!!BW]S@R!/P@:`Q\,6X(>'P$O+2G=KG6Y<*[WL5:JI\5:C/,5'CQ_XQCJ
MZ;)9E49H11LFB2F64H3+T'E#3OJ2X(4V1;M+#S3A@XVM!72Y0O.$9QQ@21@9
M>)?H(S\>@1,"`G'27FE#$3"@$+0`"FND>P&K6MYMM*_;K62^]JJ=M24+5Q(*
M3EQZ00,8Y2>([2E1L/O!;=Q-(9&K75.)<0A/_D!]<$8"1F90Y'^TA$_9!^U!
MX0>0_P#4_P`?>6_Y_N[G\#DK];S7"F@,^PER_F#_`"\D>_\`?_=Y\_;E.?T<
M8Z,?S$H?Y5?S.D,OPWWF7+-EX2^E\D&F5*0"`(CPI2O-R@`>DPCPIK0PM:`E
M+>.8Q*10A:R\N4@(CY/F+NJ!&;G<M,]J&&9LK[#^$)N0-?4VU2$C.\<B)H"S
M7:(K<XA(P4,D8O(-`*5TF8>T-&#L=MTY:J8ZM=]2Z5`RA)PDUQF>TP.6YNKF
M:]X62D/U#:R9CCFX8&$R[?Z6.X:Y.G5</4):Q2Y;1AKX38L[1$AC3,EC-JR4
M:S-_$;@7Q0"/NGD9IH4J=`PJ@:@4U)#FYMAI]7_9!]P$+:(*N07,>K/IC56M
M&73X!\9;3ZX5A]&7'T09'H/=1HVQ[=7&6GD.YE8S;QG%XQM>]4G`'7C("Y5J
M-;=O!8I3`9HW8F,9%80*;F\<!'LUKF\^WR-3Z<^)4(S55(,R)<5#F!Z9QE=M
M-0&P7GW*JD*>IP6>$L<"<<3,RPQE$EVS>M7S5L\9JD<-'B"+ILX2'F26;N$B
MK(K)G`1`Q%$S@(#H%AWWO!IZD26.'D@I&W$/([QHYDRC,(A2@!0`-^/UZ]<Q
M4DSY&4>:U%223QF!$<-\S1]Y=+?PUM/^SV.C8V!^YI_B%_I0,V[OWD_PT?HJ
MAPU\K!]WQ='\9KN_K2^H<W^^_"?X<>F)+VF^[)_:_,(4!ZWWW8>Z/]R5/V@Z
MTO;#[_V_]NGYXV/7OW5K/H&(_P`Z.(E#J2;3A$W'XN$`+W_J4..C2W<=>.@J
MYA"FPG(,#QY0.6@E$:C9^K"AWXQ\JO1\\2L(\%*\>`FI00&O$>T*\*:YV!W)
MF29>B"]*SE(/##AQB\#\>PWY/Y=-+PD<!YX\Q*?XT,^,VNV#'K.13F4,0D>C
MN/LE1TJ?BFF1)\!A,81X`!1[==-=*4]0[X2BRR)U:;.3(=BHX\:J?9HO&>:A
MXRIVM1I<)^DML^D0\!**:A2F`0,40`Z9@[!*<`,00$.%!*(:YEN!:62D?WAP
M^7G'84K8>4%JQ(D1Y0(2YZP\[$QFQ/*,:_<@W=W$O`QL0B8*"Z=-YV.?+I%J
M-0$K5L<]?0&I[\,=OJ[KN]:RVGZMHE2NP`X]D##XP*VGHMF*]-0L"H?=;2V.
MGUDDCR`3A.S:5!O8KHV[EI1VB9%K/-KQ<1QCCQ5192[1N=0I1[`$YPIZ=3WN
MM64-7XO+4BC5F;144P5VY%0.FT-%6T?@PU"[4((+C52I$^8*TXQK?3HAI&X^
MFIO7@X8JAY63B;Z:L")!_.J+'B5^4A`#C500I^'5SX@:UFW>(73U7584;3C*
MR>I2T^B46'AJMS]R\-VL*.C&:M?I76P.<ULD>B-XZ"-PPS0N=+,56(6XB&AI
M7RO#Q%6/FUF2ABF$0$QDG29N8*<`"NL3XVJ-\JLUPI@3;LQ,^4R$GT1DO`'>
M&&3?;,^0+BD(6$GB9$@RZ9$"'(O,0I!$0$.(5IQ,(C0.&@9<:<<(*"`9S\D=
M)BZEA.<B8D#ATF&V_7QN*(5=X,M9-0AYT65P20-RT%0C3S[1L4AQK4HK*&`0
M"G'1V>"YNH;>O%T0DII^[",QX3D21\D<UO\`]!+FPXNQV5M055**EJ2.(!P'
MG)@[/PU,_P#QS]P^2-[W^S3XODJ#XO+Y3Q^6E*\_A<::B3XS;O\`<Q\1S?Z#
MXU/-RXRGYXG3X+5_[/\`X5W9]]^SOL\^'X(X-U[NI9&;&]KBU@V7<[-CG_.Z
M3NUK.9MWK="5MVVE$13N2[#\ROC,%&C-P'E#F*`**%,`=FH]VGT*YK*^!#^5
M%K9&968R)ZL>,3]K;4+UFL9]T255B\.!,@>SM$NV&'_3TV?7EU#-V5DX-MUT
MG(M9F9+=65[E<.^<L=9;>0"1NIX\<%.*@R$VW!RB@:H5<'"E>S19ZOU50:+L
M+CR5HSMM]TVA)F292!,#UIG3=7J*](2ZAQ`*LRB<.!F9'I&!Z8E2H?!.,[>P
MFQV^1MLQJ6+&=AIXW"W#LVIF2MNDA0A#>80\($572R!?$.IR\QEO;^MQT`:;
MD_4W==Y6M?OA>[P&9XS\\H+=NWT[5O%M0!W"6\@'5*7GYQ%X]5#8I<73TW8W
MEBZ30*UQY/NU+OPU-^()6S^U'CCQV;!NX.<H#(6Z(II+``B)#B&C_P!O=:46
MK-*)-6\VFO;3D*3@)C`S!X]1@3M66*KLE]4.Z66"<P*>@XC'KGCT0[X^7-ZH
M\3N>PPSV@97NQ)_G["<*J2VWCY^@N^O[&;`"$8O$%A.9:1EH!/F!Z;VN5,Z=
M:!30M;P:+8T]?OBE"4&@<,_5/!1X^0Q-FV^J7KE3"WUB5BK2F8F"!(<L>C&'
M/`%.-`$2T*/KK3UB(ZB%80I)R\3C$F/36L9)9.<1OOS-;MHCU,)9-=R@BH.-
M+5,4BJR:9A*#!@',!3&*:G'MT9NPKC5/I%1J7VT-]^H@'`XGM@:]V*>H7?R\
M&UJ;[M(F`>("H<-_*MKIK]/6ZCHJI*E#--WE`Z9RJ$$0>+A2I1$*AJ(-^WF'
M=;A;"PMON!B(DG:MIQO3I;4E25YYR5V0H'UP%`2Z86Z8ZQB)IDLDXF.<P$*7
MVQ$1,8P@`!K3=M"E.N[:YF"4>\)F3T1GM=$_91\*25+4F1`ZXC!<39AN["UZ
MVKE'&-XFM*_+24*]MVY8QRS!_%NC)E`R[;QP72`X@`?6*(<-'K=FK->:1ZVW
M$LNTKF!,\988<8%*FJ+G:ZX5-`AQ#B%3Q!/K`G'E"C@]<WJ=B83?;/R'4W$:
M.[;#\@1```?1PUH*=L-M0)>[L$=HC85ZWUPMPN!YX*/0DR@#US>IX`"(;T,B
M5IP_IEN=O=_VC2.V&VI!`IF)RZ1"&M]<@@]^_P`?R3!S]N60\Y[JYJP[]D+M
M<Y"W`7I(IS2<[)OF24O-W%'G(JU$%&Z:*7G#&-[`%)Q'NT1UD>T;H[:A-!?'
M`S95TIIW$@YE)0<)B7/'C'/;<&WZNU!OS4U5D86Y?#4IJ!@0%+1C+^B'1N(>
MMMB.W[4C[0W%VC=]CY0M9!.!N9LRC%9`CF5B_P"A+KBP22\['\Y40,(*\35J
M'`0T$^H?"WJBXU*KMH*HI:O3U2HK965@$!6(2H3Y0;^EO&=I.@MXM6XM%6T&
MH:63;H#94E10`,PD,)RX<83WW8;H,I]4[)=G8/V_V/,CCZ#FP721%5-859!V
M8S=:X[I?MB>6AHYM%JG%--QRCST*`B8>,[;8:!T[X=;+4ZSU]7,'5):(2AM0
M4D)RSR`<U%7,=D#_`+N[I:C\46HJ+1N@**H&G&Z@$K6DHX^KF5.6&7IA:K/.
M&HC;YTP<H8JC?!$ELX=<)RBZ=`1=3*KJ+/+/"&J`<KAYS&"O&@Z$K2NJW=9;
M^6[4Y)#E7<@4!1P"!,)!Z))@SM<:(:V_\,EVTK0#,JGM2@KGF6HHSREQQ&$%
M/Z$247*[?,M,E/`?L75]2#1T@;D60426(*2J*P!S%$I@-0:]VI6\9]4A>X-"
MY1*S/,4;1FDXYDF<1%X%*(G;RZ,5S93WU0`L*$DD9)8`]I@A.4\:9YZ5F[*1
MS19-NOYW#\U.2*K)XR`ZL-(6M+*BY<P=Q+D`S>)>M5%E?`,L8I0$0&@ZEVT7
MO1OB1VVI=*W:J12ZNIFQZJO5]=*<H5CB4F0X<X@2]:1U[X6-VW=866G76:->
M<40L>M-IPS*5`<%)GAA*%,#]=;:N2T$Y<T!>871Y0J@VJ#,`;^;\,!,W"XA1
M]UBW!3AXGU>74`_[0]UA<C39Z+W+O)!T/)RA$Y3E/C+&4$\?')M/\*-0VU7*
MN:4B;'<JF5D<C*4@><)DV)BS/'5BW3(YDNBWI&VL.1LS&!(2L@"Q(>/M.'4!
M5O!VNL)2(3$D^!),7!VYC$Y@&H:(2_Z@T=X:MME:4M=2W5ZOJ`2L(Q]=0*9S
M&(2)P,MCT5KWQ2;NC6E^IW*32*%)""J8`;000`#S,L8=B_`]O?!?P#[L;_"W
MP_\`#?NKPR^7]U>4\KY;P^SD\/NUSH^(U/Q#XM,^]][WD^>;-FCJQ\'HO@WP
M'(GW#N.YERRY<O9PCP+MPSBB_P!\UDK]Q;CN^)!F@+9K(7A9ELW,_:MQ`0\!
ML\G(Q^X01H(U*0P%]6FTM?<Z`$4-2ZU/CE4I,_S2(NG[=0U/]^A*_I`'T@Q2
MT\,8GL.2<RMBXLQW8\@Z;$:.9"T+*M>VI!TV34%4C99["1C%RJW(H/,!#&$M
M>[2K*^X5K815ONN@&<EJ4K](F&T]!1TKOO%.TA#TI3"4C#R`1TXI3`%!XAZZ
M5IZ!U9J2%24!)47RR#(CC..?7KB;&>15F#J_<<6%?#B*342C5KPL^W+G69)+
M&*=9%FK.1KY1HFJ8H"8$Q*!A#CJ]IZZMHD%-&\ZV"<<JE)G^:1%D_14M4^%U
M+:%I`YI!](,>=:V#<,V/-)W%9.(,8V=/H(+M6\[:]A6G;TNBU=E*5VV2DH>)
M9ODV[HA`!1,%`(H``!@&FF/7&YUP+5>\ZXSRS+4K](F&M6ZBI5=[2-MH>Z0E
M(]`$=0*4X_6*``(C6@_EU;(GE(.'1V1>Y&Y3_&^>.873A'#]\ROOV]L2XRO"
M:%(&YI>Z+#M2X94Z!!`$T32,Q$O'HI%`H4+S\H4U<IN-TI&.ZH7W4#H"U)'F
M!`BS>H*2K,ZMIM?:E)](,;+:EAV=848:'L.S[6LJ)47.Y4B;4@(BVXX[E01%
M1R=E"M&34RYQ&IC"7F-WCKR=J*JJJ>_K'%N'+*:B5'SDDRBZIV*:F1W;*$H1
MU``>881ZMPVY!77$.X*Y82'N*%D"`D_AY^,93$4\2[R.HZ00<LW)?T5"&+JB
M'7F7$NL*4EQ)P()!\XD1"<;:>3W;R0IOH(F/ECD9=L6W$H<OV><'#3A[.*+`
M`*4H%`^'^&L@J]7P^S65`_Q'/UHL%6NU@^K2LD?01^"*_9CVX?Y>,'_X46!_
M=[3?C-]_?:C_`#'/UHI\,MO[HQ^8C]6*?9CVX?Y>,'_X46!_=[2^,W[]]J/\
MQS]:%\,MO[HQ^8C]6-BA<)XEMATQ>6QB['=N.HT_/'N8.RK9BEF!^Y1B=C&(
M&:*%[C$$HAKU?OEZK*55)6U=0ZTKB%.+(\Q,8ZGTKIRDN*;NQ04R;D,.\#:`
MK'CZP$XT?(>TW;QE=\I*Y!Q%9EQ2JJAE%9%6);,GZYS``&5=O(XK5=TH8`XB
MH8XZS5DW$USIAD4MCN-2U2@8("_5'6`9R\DHP=]VJV[U'5*K;S::.HJUF:E*
M0`3VRE/RX]<=`L'$6.L6L0CL=V-:UGM@1(V-[BAHY@Y60)02D=OD&Y'CR@A7
M^<.;6%NVH+_J&H557ZK>J5JG@M1(GV3D/)&>L>D],Z;9[BP4%-1I`XMH2#YP
M)R\L;I*P[&;8.8J7C6,I&O41;NX^0:MWC)RD(@(I.6CDBC==$1+42F*(5`.&
ML6TX_2+0[1*+;[9FE:3)23U$8CR1EZFD8N%&JDN#:7:=8DM"@"E0ZP<#'D6Q
M8]K6:V79VK;%NVPT=*F7<M;=AXZ&;N%C\3*K(QS9LFHJ(]IC`(ZNZRXW&XO"
MHN#[KSR1(%:E*,NU1)BRMU@LMGIS2VBF:IF'#-:6TI2)]@`CT9VW(>Y(Y>*G
MH:*G(QP6B\9,,6TDQ<4#AXC5XFLW,/K$NK:EJJ^BJ/>J)Y3-1^4@E)EVB4>]
M=:K;=:<4-S9;?HOR5I"AVX@P6H-C6U'WN,\."[$"346\RHH6-+Y?Q:\W!@8?
M(`3F'ZH)@7U4UO+>Z6XS=+[F+Q5]QT9SZ>,1PK8S:85AKF[)1IJ2J>8(D9]/
M1!EH*VX2V(MM"VY#Q<#$M0Y6\9#L6D8P0`:5\)HR210(8:<1`O'6D5=157&L
M-=<'G'J@\2M142>TDQ)5);J"W4J:"W,ML4:1[*`$CS"4>_ZM>47DL)<HL#GK
MQ[/P:45B_2A10U:>SVU]7Y]*%`"M./;I0HKI0H&E"@:4*!I0H&E"@:4*!I0H
>&E"@:4*!I0H&E"@:4*!I0H&E"@:4*!I0H&E"C__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
